Mr. Charles Vandiver is the Chief Executive Officer, Owner, and Senior Consultant Pharmacist at Consultant Pharmacists of New Mexico. Mr. Vandiver acquired a B.S. in Pharmacy at the University of New Mexico College of Pharmacy (UNMCOP), class of 1981. Mr. Vandiver’s professional career has included hospital pharmacy, consultant pharmacy, clinical practice as a pharmacist clinician, and business entrepreneurial directions. Mr. Vandiver is known as an initiator and innovator of progressive pharmacy practice. He is a recipient of the Pharmacist of The Year Award (NMSHP), and the Dorothy Dillon Award (NMSHP) for hospital pharmacy and professional excellence.
Mr. Vandiver resides in Albuquerque, New Mexico. He has two sons, Nathan and Nicholas. Mr. Vandiver’s out-of-profession escapes include travel, current events, and music. Mr. Vandiver is a singer-songwriter and has been nominated by the New Mexico Music Awards (2011, 2014) for best songs, in Country, Bluegrass, and Contemporary.
2020: Mona N. Ghattas, class of 1984
2021: Michael C. Raburn, class of 1987
2022: Ronald R. Marotto, class of 1966
2023: Katrina A. Mealey, class of 1986
Adam was born and raised in Albuquerque, NM. He completed his Doctor of Pharmacy in 2016 from the University of New Mexico (UNM) College of Pharmacy (COP). He then completed a two-year research fellowship in Multi-Center Clinical Trials at the Department of Veterans Affairs Cooperative Studies Program (VA CSP) Clinical Research Pharmacy Coordinating Center. In 2018, he also completed a Master of Science in Pharmaceutical Sciences from the UNM COP, having a concentration in Pharmacoeconomics, Epidemiology, Pharmaceutical Policy and Outcomes Research and an emphasis in Clinical Trials Research.
In his capacity as a Clinical Research Pharmacist and Assistant Center Director at the VA CSP Pharmacy Coordinating Center, Adam has been involved in the planning and conduct of multiple large, multi-center, clinical trials sponsored by various entities including VA CSP and the National Institutes of Health. His work was instrumental in implementing the first-ever use of direct-to-participant mailing of investigational medication to both Veteran and non-Veteran participants in one of the largest clinical trials ever conducted in adults 75 years and older (The PREVENTABLE Trial, J Am Geriatr Soc. 2023 Jun;71(6):1701-1713). Adam served as a subject-matter expert providing guidance to the Clinical Trials Transformation Initiative when updating the Recommendations to Sponsors for Planning Decentralized Trials. Additionally, Adam has served as a member of the UNM COP’s Graduate Affairs Committee since 2019 and helped to establish the Master of Science in Pharmaceutical Sciences concentration in Clinical Trial Design and Management.
2020: Dr. Adriane N. Irwin, class of 2010
2021: Dr. Davena M. Norris, class of 2012
2022: Dr. Monique R. Dodd, class of 2014
2023: Dr. Keenan L. Ryan, class of 2014
Dr. Todd A. Conner was selected as Director of the U.S. Department of Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center (PCC) in 2020. Prior to that, he was the Deputy Director, Assistant Center Director, and completed the Clinical Trials Fellowship at the PCC. He received his Doctor of Pharmacy in 2005 from at the University of New Mexico (UNM) College of Pharmacy (COP) in Albuquerque, New Mexico. He then completed a General Practice Pharmacy Residency in 2006 followed by a Nephrology Pharmacotherapy Fellowship in 2008 both at the UNM Hospitals and UNM COP, respectively. At the PCC, his duties as Center Director include establishing and maintaining extramural research collaborations with Industry, University, and the National Institutes of Health partners, balancing the VA CSPCRPCC’s research portfolio that includes support to over 80 clinical trials funded within and outside the VA Office of Research and Development, maintaining and establishing educational affiliations, and overseeing CSP and PCC strategic planning and quality initiatives. Some of his highlighted research contributions include the pivotal trials: “Drug-eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty” (Lancet. 2018 May 19;391(10134):1997-2007); “Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine” (N Engl J Med. 2018 Feb 15;378(7):603-614); and “Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy” (N Engl J Med. 2013 Nov 14;369(20):1892-903). Through these trials and numerous other ongoing research initiatives, he is committed to fulfilling the VA’s mission of improving the health and wellbeing of our Veterans and the Nation.
2020: C. Frank Bennett, class of 1980
2021 Dr. Brian J. Werth, class of 2010
2022: Dr. Hengameh H. Raissy, class of 1999
2023: Dr. Katrina A. Mealey, class of 1986
Nawarskas is Associate Professor of Pharmacy at the UNM College of Pharmacy (COP) and Associate Professor of Medicine at the UNM School of Medicine, Division of Cardiology. Dr. Nawarskas provides didactic and experiential teaching in several courses at the UNM College of Pharmacy focusing on cardiovascular medicine and also provides clinical pharmacy services at UNM Hospital with the Division of Cardiology. He was recently named Director of Professional Curriculum Assessment and Quality Improvement at the COP and is actively engaged in the scholarship of teaching and learning.
Feng is an expert in biochemistry and biophysics of metalloproteins and oxidoreductases. He has authored more than 96 scientific manuscripts and has been continually funded by the NIH. He is an active grant reviewer for NIH, NSF and French National Research Agency. His lab focuses on the central question of how Nature has optimized protein dynamics to promote electron transfer. This question forms his life’s work and is a source of endless fascination for him. The Feng laboratory is active in an innovative combination of cutting-edge approaches, including laser flash photolysis, pulsed EPR, ultrafast 2D IR, genetic code expansion and computational chemistry.
The goal is to understand what the function of a biological relevant metal site is, how it achieves its function, and what factors dictate its function. Feng’s recent studies of the NOS proteins demonstrate that functional domain motions and interdomain docking play a central role in NOS isoform function by modulating key electron transfer processes. Molecular mechanisms of NOS regulation are potentially key targets for development of direct, selective new pharmaceuticals for treating several diseases that currently lack effective treatments.